title: TAT and PAP in hemodialysis patients: two cats in a bag?
authors.forename: I C
authors.initials: IC
authors.lastname: Haznedaroğlu
authors.forename: Y
authors.initials: Y
authors.lastname: Erdem
authors.forename: S
authors.initials: S
authors.lastname: Dündar
authors.forename: S
authors.initials: S
authors.lastname: Cağlar
authors.forename: S
authors.initials: S
authors.lastname: Kirazh
mesh_terms: D000328:Adult; D000933:Antifibrinolytic Agents; D000990:Antithrombin III / Q000378:metabolism*; D005260:Female; D005341:Fibrinolysin / Q000378:metabolism*; D006801:Humans; D007676:Kidney Failure, Chronic / Q000097:blood* / Q000150:complications / Q000628:therapy; D008297:Male; D010447:Peptide Hydrolases / Q000378:metabolism*; D006435:Renal Dialysis / Q000009:adverse effects*; D013927:Thrombosis / Q000097:blood* / Q000209:etiology; D000979:alpha-2-Antiplasmin / Q000378:metabolism*
chemical_list: D000933:Antifibrinolytic Agents; D000979:alpha-2-Antiplasmin; C046193:antithrombin III-protease complex; C037742:plasmin-plasmin inhibitor complex; D000990:Antithrombin III; D010447:Peptide Hydrolases; D005341:Fibrinolysin